Safety and benefit of Pemafibrate in medical practitioner

A prospective observational multi center trial for safety and benefit of Pemafibrate in medical practitioner - PAR-CHAT (PARMODIA-Chikushi-Anti-Dyslipidemia Trial)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041837

Enrollment

200

Registered

2020-09-18

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hyperlipidemia patients treted with Pemafibrate

Exclusion criteria

Exclusion criteria: 1)Hypersensitivity for Pemafibrate 2)High LDL-C alone 3)Severe liver damage liver cirrhosis or bile duct ofstraction 4)Renal dysfunction more than grade3 5)Cholelithiasis 6)Pregnancy 7)Under medication with cyclosporine or rifampicin 8)Judged as inappropriate patient

Design outcomes

Primary

Measure	Time frame
Clinical laboratory data of triglyceride and high density lipoprotein-cholesterol post 24months treatment	—

Countries

Japan

Contacts

Public ContactHidenori Urata

Fukuoka University Chikushi Hospital Department of Cardiovascular Diseases

uratah@fukuoka-u.ac.jp092-925-4007

Outcome results